171 related articles for article (PubMed ID: 1649059)
1. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells.
Del Bino G; Skierski JS; Darzynkiewicz Z
Exp Cell Res; 1991 Aug; 195(2):485-91. PubMed ID: 1649059
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
Del Bino G; Darzynkiewicz Z
Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159
[TBL] [Abstract][Full Text] [Related]
3. Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells.
Hotz MA; Del Bino G; Lassota P; Traganos F; Darzynkiewicz Z
Cancer Res; 1992 Mar; 52(6):1530-5. PubMed ID: 1540962
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation.
Del Bino G; Bruno S; Yi PN; Darzynkiewicz Z
Cell Prolif; 1992 Nov; 25(6):537-48. PubMed ID: 1333822
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay.
Gorczyca W; Melamed MR; Darzynkiewicz Z
Toxicol Lett; 1993 Apr; 67(1-3):249-58. PubMed ID: 8383887
[TBL] [Abstract][Full Text] [Related]
6. Effect of camptothecin on mitogenic stimulation of human lymphocytes: involvement of DNA topoisomerase I in cell transition from G0 to G1 phase of the cell cycle and in DNA replication.
Bruno S; Giaretti W; Darzynkiewicz Z
J Cell Physiol; 1992 Jun; 151(3):478-86. PubMed ID: 1338332
[TBL] [Abstract][Full Text] [Related]
7. Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.
Inaba M; Mitsuhashi J; Kawada S; Nakano H
Jpn J Cancer Res; 1994 Feb; 85(2):187-93. PubMed ID: 8144400
[TBL] [Abstract][Full Text] [Related]
8. A new action for topoisomerase inhibitors.
Zucker RM; Elstein KH
Chem Biol Interact; 1991; 79(1):31-40. PubMed ID: 1647887
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors.
Bertrand R; Solary E; Jenkins J; Pommier Y
Exp Cell Res; 1993 Aug; 207(2):388-97. PubMed ID: 7688316
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
11. Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment.
Zucker RM; Adams DJ; Bair KW; Elstein KH
Biochem Pharmacol; 1991 Nov; 42(11):2199-208. PubMed ID: 1659821
[TBL] [Abstract][Full Text] [Related]
12. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
13. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
D'Arpa P; Beardmore C; Liu LF
Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes.
Kaufmann WK; Boyer JC; Estabrooks LL; Wilson SJ
Mol Cell Biol; 1991 Jul; 11(7):3711-8. PubMed ID: 1646393
[TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity.
Poot M; Hiller KH; Heimpel S; Hoehn H
Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696
[TBL] [Abstract][Full Text] [Related]
17. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro.
Backer LC; Allen JW; Harrington-Brock K; Campbell JA; DeMarini DM; Doerr CL; Howard DR; Kligerman AD; Moore MM
Mutagenesis; 1990 Nov; 5(6):541-7. PubMed ID: 2175833
[TBL] [Abstract][Full Text] [Related]
18. Two specific topoisomerase II inhibitors prevent replication of human cytomegalovirus DNA: an implied role in replication of the viral genome.
Benson JD; Huang ES
J Virol; 1988 Dec; 62(12):4797-800. PubMed ID: 2846890
[TBL] [Abstract][Full Text] [Related]
19. Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine.
López-Baena M; Mateos S; Piñero J; Trinidad Ortiz ; Cortés F
Mutat Res; 1998 Oct; 421(1):109-16. PubMed ID: 9748527
[TBL] [Abstract][Full Text] [Related]
20. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells.
Roberge M; Th'ng J; Hamaguchi J; Bradbury EM
J Cell Biol; 1990 Nov; 111(5 Pt 1):1753-62. PubMed ID: 2172257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
